Biogen reports Q2 adjusted EPS $5.47, consensus $3.87

Reports Q2 revenue $2.6B, consensus $2.32B. “We delivered another quarter of strong execution against our strategy to transform our portfolio and build the new Biogen (BIIB). Our performance reflects robust financial results, ongoing cost discipline, continued growth of our launch products, and meaningful strides expanding and advancing our late-stage pipeline. We are now progressing salanersen to registrational studies in SMA following exciting interim Phase 1b results, and have initiated all three Phase 3 studies for felzartamab in rare kidney disease. These achievements reinforce our commitment to building a stronger company, with the potential for sustainable growth and long-term value for our shareholders,” said President and Chief Executive Officer Christopher Viehbacher.